Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 11Myeloid 3Lymphoid 3CNS 3Sarcoma 2Plasma cell 2

Conditions

Gliosarcoma 2Glioblastoma 2Pinealoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Medulloblastoma 1Glioma 1Brain Neoplasms 1

Interventions

Temozolomide 102Radiotherapy 47Bevacizumab 33Carboplatin 23Irinotecan 20pembrolizumab 17Radiosurgery 16Nivolumab 16Radiation 14Cyclophosphamide 11Magnetic Resonance Spectroscopy 10fludarabine 8Trastuzumab 8Radiotherapy, Intensity-Modulated 8Carmustine 8Surgical Procedures, Operative 7Specimen Handling 7Pemetrexed 7Paclitaxel 7Interleukin-2 7Filgrastim 7Everolimus 7Erlotinib Hydrochloride 7temsirolimus 6Vorinostat 6Radiotherapy, Conformal 6Lomustine 6Ipilimumab 6Granulocyte-Macrophage Colony-Stimulating Factor 6Gemcitabine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × plerixafor × CNS × Clear all
NCT00669669 2022-05-18

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
12 enrolled 13 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT01977677 2018-10-23

Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma

Stanford University

Phase 1/2 Completed
30 enrolled 11 charts
CNSSarcoma

Glioblastoma, Glioma, Medulloblastoma, Pinealoma, Neuroectodermal Tumors, Primitive, Gliosarcoma

NCT01288573 2017-05-16

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Sanofi

Phase 1/2 Completed
46 enrolled
CNS

Brain Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡